H520
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Derived from a lung mass of a patient with squamous cell carcinoma, the H520 cell line demonstrates a significant reduction in p53 mRNA expression compared to normal lung tissue. This human hypotriploid cell line displays a modal chromosome count of 58 in approximately 30% of its cells, devoid of major structural DNA abnormalities. While exhibiting positive keratin and vimentin staining, it shows no presence of neurofilament triplet protein. Impressively,
these cells exhibit the capability to create colonies in soft agar and initiate tumor growth within a mere 21 days in nude mice.
Why choose H520 from AcceGen?
The H520 cell line from AcceGen showcases remarkable viability and quality, having satisfactorily cleared rigorous quality control assessments. It maintains sterility and is devoid of bacterial, fungal, mycoplasma, and human pathogen presence, including HIV, HBV, and HCV. Furthermore, the cells are cryopreserved using advanced techniques.
| Product Code | H520; H-520; NCI-HUT-520; NCIH520 |
| Species | Human |
| Cat.No | ABC-TC527S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Squamous Cell Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The H520 cell line finds crucial applications in probing chemotherapy sensitivity and resistance to anticancer treatments. Its utility extends to the exploration of innovative therapies like antiproliferative drugs, assessment of the inhibitory impact of small ribonucleic acids (siRNA) on cell proliferation and invasion, as well as evaluating the efficacy of anticancer agents in inducing apoptosis.
